SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2003
GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its
charter)| | | | | |
| Delaware | | 0-23736 | | 52-1841960 |
|
| (State or other jurisdiction of | | (Commission File | | (I.R.S. Employer |
| incorporation or organization) | | Number) | | Identification No.) |
| | | |
| 6611 Tributary Street | | |
| Baltimore, Maryland | | 21224 |
|
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (410) 631-6300
(Former name or former address, if changed since last report)
Exhibit Index is on page 4.
INFORMATION TO BE INCLUDED IN THE REPORT
Item 5. Other Events
On July 30, 2003, the Company issued a press release announcing that the initial purchasers of its recent convertible offering have elected to purchase approximately $9.3 million in additional Convertible Subordinated Notes pursuant to an option previously granted. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
| | (c) | | Exhibits |
| |
| | 99.1 | | Press Release of Guilford Pharmaceuticals Inc. issued July 30, 2003 |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | GUILFORD PHARMACEUTICALS INC. |
| | | | | |
| | | | | |
| Dated: July 30, 2003 | | By: | | /S/ ASHER M. RUBIN |
| | | |
|
| | | | | Asher M. Rubin |
| | | | | Vice President, Deputy General |
| | | | | Counsel and Secretary |
- 3 -
INDEX TO EXHIBITS
| | | | | |
Exhibit
Number | | Exhibit Description | | Page |
| | | | | |
| 99.1 | | Press Release dated July 30, 2003 | | 5 |
- 4 -
